The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.
Some of the key takeaways from the Obesity Pipeline Report:
- Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years.
- Obesity companies working in the treatment market are D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment
- Emerging Obesity therapies in the different phases of clinical trials are- DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.
- In June 2023, Extensive findings from SURMOUNT-2, a phase 3 clinical trial assessing the safety and effectiveness of tirzepatide (10 mg and 15 mg) from Eli Lilly and Company (NYSE: LLY) for the management of chronic weight in individuals with type 2 diabetes and obesity, demonstrated that tirzepatide produced a greater reduction in weight than placebo at both doses.
- In June 2023, Carmot Therapeutics, Inc. reported encouraging outcomes from a preclinical study in rodent models of type 1 diabetes (T1D) to support the effects of CT-868 as an adjuvant to insulin treatment, as well as a mechanism of action (MOA) clinical study of CT-868 in overweight and obese adults with type 2 diabetes (T2D) to assess weight independent effects on glucose homeostasis.
- In October 2022, The US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the exploration of tirzepatide for the treatment of people with obesity or overweight who have weight-related comorbidities, according to a statement released by Eli Lilly & Company.
- In February 2022, Carmot Therapeutics commenced a parallel-group, multiple-center, randomized, double-blind, placebo-controlled trial to assess the safety, effectiveness, and tolerability of CT-868 when given to individuals with Type 2 diabetes mellitus who are overweight or obese for a duration of 26 weeks.
In addition to being overweight, obesity is recognized as a chronic or non-communicable disease that is a complex, multifactorial phenotype predominantly related with excess adiposity or body fatness, which can express physiologically and not just with regard to body size.
Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
- DD03: D&D Pharmatech
- AX-0601: ProQR Therapeutics
- NPM 139: Nano Precision Medical
- BK-1701: Bukwang Pharmaceutical
- CBW-520: Caliway Biopharmaceutics
- YH34160: Yuhan
- TERN-601: Terns Pharmaceuticals
- Thermostem: BioRestorative Therapies
- SCO-267: SCOHIA PHARMA
- CT-181: Click Therapeutics
- HM15136: Hanmi Pharmaceuticals
- NNC0480-0389: Novo Nordisk
- EMP-16: Empros Pharma
- CT-868: Carmot Therapeutics
- Tirzepatide: Eli Lilly and Company
- Semaglutide: Oral Novo Nordisk
Obesity Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Obesity Molecule Type
Obesity Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
Obesity Pipeline Therapeutics Assessment
- Obesity Assessment by Product Type
- Obesity By Stage and Product Type
- Obesity Assessment by Route of Administration
- Obesity By Stage and Route of Administration
- Obesity Assessment by Molecule Type
- Obesity by Stage and Molecule Type
DelveInsight’s Obesity Report covers around 130+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies
Some of the key companies in the Obesity Therapeutics Market include:
Key companies developing therapies for Obesity are – Alizyme, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Takeda Pharmaceuticals, Vivus Inc., Zafgan, Zydus Cadila, and others.
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
- Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Obesity drugs and therapies
Obesity Pipeline Market Drivers
- Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.
Obesity Pipeline Market Barriers
- However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.
Scope of Obesity Pipeline Drug Insight
- Coverage: Global
- Key Obesity Companies: D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others
- Key Obesity Therapies: DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
- Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
- Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials
Table of Contents
1. Obesity Report Introduction
2. Obesity Executive Summary
3. Obesity Overview
4. Obesity- Analytical Perspective In-depth Commercial Assessment
5. Obesity Pipeline Therapeutics
6. Obesity Late Stage Products (Phase II/III)
7. Obesity Mid Stage Products (Phase II)
8. Obesity Early Stage Products (Phase I)
9. Obesity Preclinical Stage Products
10. Obesity Therapeutics Assessment
11. Obesity Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Obesity Key Companies
14. Obesity Key Products
15. Obesity Unmet Needs
16 . Obesity Market Drivers and Barriers
17. Obesity Future Perspectives and Conclusion
18. Obesity Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States